| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
259,221 |
198,635 |
$20.85M |
| J3357 |
Ustekinumab, for subcutaneous injection, 1 mg |
2,197 |
1,785 |
$17.13M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
102,709 |
79,050 |
$14.47M |
| J2350 |
Injection, ocrelizumab, 1 mg |
691 |
541 |
$12.25M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
32,930 |
24,787 |
$10.48M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
79,293 |
62,712 |
$8.27M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
28,751 |
19,292 |
$6.67M |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
6,326 |
1,314 |
$5.89M |
| J3241 |
Injection, teprotumumab-trbw, 10 mg |
245 |
83 |
$4.97M |
| J0791 |
Injection, crizanlizumab-tmca, 5 mg |
1,131 |
737 |
$4.43M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
66,820 |
21,901 |
$4.08M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
34,901 |
22,763 |
$4.00M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
2,137 |
1,482 |
$3.60M |
| 64483 |
|
5,120 |
4,558 |
$3.57M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
25,988 |
15,578 |
$2.91M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
14,497 |
7,975 |
$2.76M |
| 27447 |
|
312 |
277 |
$2.63M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
9,656 |
7,713 |
$2.37M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
4,432 |
3,879 |
$1.89M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
40,727 |
23,128 |
$1.82M |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
3,520 |
2,231 |
$1.64M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
11,223 |
9,029 |
$1.61M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
6,102 |
5,146 |
$1.60M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
2,226 |
1,978 |
$1.59M |
| 27130 |
|
171 |
149 |
$1.55M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
1,170 |
859 |
$1.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
41,050 |
29,613 |
$1.31M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
37,933 |
22,087 |
$1.30M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
10,955 |
7,178 |
$1.24M |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
2,149 |
1,933 |
$1.23M |
| 62323 |
|
2,655 |
2,360 |
$1.22M |
| 71046 |
Radiologic examination, chest; 2 views |
26,854 |
20,986 |
$1.22M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
12,807 |
10,458 |
$1.13M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
20,057 |
16,898 |
$1.13M |
| 36512 |
|
1,945 |
1,278 |
$1.12M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,672 |
1,477 |
$1.12M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
23,109 |
15,105 |
$1.11M |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
708 |
479 |
$1.07M |
| J0897 |
Injection, denosumab, 1 mg |
2,244 |
1,469 |
$981K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,825 |
1,376 |
$963K |
| 93975 |
|
5,264 |
4,537 |
$947K |
| 70450 |
Computed tomography, head or brain; without contrast material |
11,287 |
8,755 |
$905K |
| 29848 |
|
725 |
653 |
$806K |
| 86900 |
|
21,495 |
15,279 |
$805K |
| J9271 |
Injection, pembrolizumab, 1 mg |
98 |
67 |
$754K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
28,938 |
25,263 |
$727K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
8,778 |
7,372 |
$723K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
28,897 |
25,226 |
$723K |
| 72110 |
|
9,222 |
8,340 |
$712K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
7,575 |
6,942 |
$694K |
| 62321 |
|
1,345 |
1,234 |
$667K |
| 97161 |
|
12,188 |
10,520 |
$621K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
4,153 |
3,525 |
$593K |
| 81513 |
|
6,567 |
5,865 |
$588K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
1,033 |
929 |
$572K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
782 |
682 |
$562K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
1,222 |
1,031 |
$557K |
| 84443 |
Thyroid stimulating hormone (TSH) |
58,325 |
50,474 |
$555K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
6,511 |
5,383 |
$546K |
| 90834 |
Psychotherapy, 45 minutes with patient |
18,983 |
9,396 |
$512K |
| 76830 |
Ultrasound, transvaginal |
5,821 |
5,023 |
$501K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
4,730 |
3,808 |
$500K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
6,111 |
5,268 |
$488K |
| 96415 |
|
7,330 |
4,689 |
$487K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
3,811 |
2,938 |
$479K |
| G0379 |
Direct admission of patient for hospital observation care |
581 |
421 |
$465K |
| 20610 |
|
2,445 |
2,068 |
$459K |
| 11104 |
|
2,656 |
1,769 |
$453K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
2,510 |
2,163 |
$453K |
| 11102 |
|
4,861 |
3,451 |
$452K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
27,197 |
23,798 |
$445K |
| 94060 |
|
2,731 |
2,443 |
$444K |
| 59025 |
Fetal non-stress test |
3,444 |
2,150 |
$444K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
3,188 |
2,568 |
$430K |
| 72100 |
|
9,127 |
7,612 |
$429K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
26,683 |
23,239 |
$424K |
| J9312 |
Injection, rituximab, 10 mg |
235 |
79 |
$418K |
| 72141 |
|
2,457 |
2,125 |
$417K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
11,574 |
5,603 |
$394K |
| 82947 |
|
142,154 |
104,378 |
$389K |
| 73221 |
|
2,211 |
1,877 |
$377K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
5,476 |
4,448 |
$359K |
| 76536 |
|
5,680 |
4,859 |
$355K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
19,493 |
16,351 |
$355K |
| 72050 |
|
4,148 |
3,768 |
$345K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
2,787 |
2,423 |
$336K |
| 22612 |
|
47 |
38 |
$311K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
958 |
806 |
$296K |
| 95911 |
|
848 |
709 |
$291K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
11,125 |
10,005 |
$289K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
448 |
278 |
$285K |
| 96920 |
|
2,088 |
387 |
$280K |
| 96900 |
|
10,613 |
2,258 |
$278K |
| J1628 |
Injection, guselkumab, 1 mg |
47 |
37 |
$276K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
46,478 |
40,939 |
$275K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
4,037 |
2,525 |
$275K |
| J9310 |
Injection, rituximab, 100 mg |
101 |
41 |
$262K |
| 71250 |
|
5,245 |
4,081 |
$258K |
| 36415 |
Collection of venous blood by venipuncture |
306,317 |
217,116 |
$253K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
139,632 |
101,729 |
$252K |
| 83718 |
|
37,677 |
34,704 |
$247K |
| 71045 |
Radiologic examination, chest; single view |
7,165 |
5,465 |
$237K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
10,014 |
8,766 |
$236K |
| 36430 |
|
2,077 |
1,197 |
$235K |
| 82310 |
|
122,959 |
95,473 |
$232K |
| 86803 |
|
24,772 |
21,712 |
$231K |
| S9480 |
Intensive outpatient psychiatric services, per diem |
2,524 |
389 |
$227K |
| 97162 |
|
4,841 |
4,131 |
$224K |
| 77065 |
Tomosynthesis, mammo |
2,388 |
1,911 |
$219K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
35,138 |
11,793 |
$217K |
| 77080 |
|
3,496 |
3,108 |
$216K |
| 72040 |
|
4,713 |
3,991 |
$209K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,860 |
12,992 |
$209K |
| 86480 |
|
8,403 |
7,272 |
$204K |
| 76770 |
|
2,982 |
2,513 |
$200K |
| 11100 |
|
1,142 |
859 |
$200K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
30,652 |
23,834 |
$197K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,006 |
1,608 |
$193K |
| 76641 |
|
2,929 |
2,490 |
$193K |
| 97165 |
|
3,013 |
2,595 |
$191K |
| 17110 |
|
5,157 |
4,383 |
$190K |
| 93971 |
|
3,409 |
2,731 |
$190K |
| 11900 |
|
2,963 |
2,619 |
$182K |
| 93017 |
|
3,075 |
2,465 |
$174K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
9,005 |
3,503 |
$168K |
| 74183 |
|
923 |
758 |
$168K |
| 85027 |
|
56,952 |
43,888 |
$166K |
| 97035 |
|
2,114 |
1,014 |
$164K |
| 87481 |
|
6,563 |
5,864 |
$160K |
| 72156 |
|
1,176 |
1,014 |
$160K |
| 76642 |
|
2,957 |
2,568 |
$152K |
| 64650 |
|
720 |
617 |
$152K |
| 95806 |
|
1,352 |
1,218 |
$151K |
| 70496 |
|
2,026 |
1,638 |
$146K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
1,387 |
879 |
$143K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
15,476 |
3,774 |
$142K |
| 82607 |
|
16,372 |
14,308 |
$140K |
| 63047 |
|
79 |
66 |
$138K |
| 82728 |
|
21,606 |
17,929 |
$137K |
| 94010 |
|
3,919 |
3,190 |
$130K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
18,870 |
13,697 |
$128K |
| 72197 |
|
504 |
410 |
$128K |
| 86003 |
|
1,936 |
1,490 |
$122K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
14,686 |
6,306 |
$117K |
| 93970 |
|
1,101 |
872 |
$116K |
| 86780 |
|
11,268 |
9,764 |
$116K |
| 36593 |
|
937 |
615 |
$115K |
| 87536 |
|
2,835 |
2,441 |
$113K |
| 88142 |
|
9,597 |
8,633 |
$110K |
| 77066 |
Tomosynthesis, mammo |
1,144 |
1,008 |
$110K |
| J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
58 |
37 |
$110K |
| 77336 |
|
1,734 |
516 |
$104K |
| 64721 |
|
72 |
68 |
$102K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,070 |
1,871 |
$101K |
| 58558 |
|
116 |
91 |
$101K |
| 95812 |
|
605 |
527 |
$100K |
| 86235 |
|
4,017 |
3,221 |
$98K |
| 87340 |
|
17,103 |
14,417 |
$98K |
| 29888 |
|
19 |
15 |
$98K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
1,138 |
598 |
$96K |
| 72158 |
|
538 |
444 |
$95K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
7,271 |
6,670 |
$94K |
| 17311 |
|
558 |
381 |
$90K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
28,791 |
23,456 |
$90K |
| 97116 |
|
4,265 |
2,269 |
$89K |
| 88184 |
|
725 |
597 |
$87K |
| 26055 |
|
152 |
116 |
$86K |
| 83550 |
|
21,915 |
18,203 |
$86K |
| 95708 |
|
269 |
126 |
$84K |
| 70491 |
|
670 |
573 |
$84K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,636 |
2,902 |
$82K |
| 74018 |
|
2,523 |
2,080 |
$82K |
| 72082 |
|
1,345 |
1,256 |
$81K |
| 96417 |
|
2,059 |
1,053 |
$81K |
| 83970 |
|
6,429 |
5,294 |
$79K |
| 73564 |
|
2,180 |
1,389 |
$76K |
| 84132 |
|
135,233 |
102,309 |
$76K |
| 70486 |
|
1,330 |
1,151 |
$73K |
| 84439 |
|
16,050 |
13,938 |
$72K |
| 73700 |
|
1,004 |
854 |
$72K |
| 17000 |
|
5,250 |
3,968 |
$70K |
| 84153 |
|
6,681 |
5,708 |
$69K |
| 83540 |
|
22,439 |
18,603 |
$65K |
| 72070 |
|
1,573 |
1,351 |
$65K |
| 90832 |
Psychotherapy, 30 minutes with patient |
3,427 |
2,149 |
$63K |
| 86160 |
|
5,639 |
4,496 |
$62K |
| 10005 |
|
162 |
138 |
$62K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,176 |
1,681 |
$62K |
| 84403 |
|
3,815 |
3,291 |
$61K |
| 96367 |
|
2,830 |
1,733 |
$61K |
| 86706 |
|
10,389 |
9,081 |
$59K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
44,452 |
33,417 |
$59K |
| 82784 |
|
8,265 |
6,491 |
$58K |
| 95811 |
|
96 |
81 |
$57K |
| 82570 |
|
23,865 |
17,832 |
$56K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
4,081 |
3,256 |
$54K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
14 |
12 |
$54K |
| 64493 |
|
58 |
51 |
$53K |
| 82670 |
|
2,911 |
2,489 |
$53K |
| 84702 |
|
10,231 |
8,000 |
$53K |
| 88342 |
|
4,049 |
3,138 |
$52K |
| 95910 |
|
238 |
219 |
$52K |
| 73130 |
|
4,627 |
2,946 |
$51K |
| 87510 |
|
3,192 |
2,828 |
$49K |
| 87480 |
|
3,192 |
2,828 |
$49K |
| 86762 |
|
5,322 |
4,180 |
$49K |
| 86147 |
|
1,284 |
1,080 |
$48K |
| 83516 |
|
6,907 |
5,039 |
$48K |
| 87660 |
|
3,143 |
2,780 |
$48K |
| 86038 |
|
7,591 |
6,361 |
$48K |
| 71271 |
|
629 |
557 |
$48K |
| 86360 |
|
2,387 |
2,013 |
$47K |
| 72131 |
|
873 |
753 |
$45K |
| 82105 |
|
3,647 |
3,258 |
$44K |
| 29827 |
|
14 |
13 |
$43K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,363 |
1,113 |
$42K |
| 95909 |
|
221 |
185 |
$42K |
| J0517 |
Injection, benralizumab, 1 mg |
19 |
13 |
$42K |
| 10060 |
|
315 |
259 |
$41K |
| 86140 |
|
17,238 |
14,329 |
$41K |
| 95700 |
|
481 |
411 |
$41K |
| 77091 |
|
1,137 |
1,052 |
$41K |
| 73030 |
|
3,975 |
3,153 |
$40K |
| 82043 |
|
13,507 |
11,685 |
$40K |
| 84270 |
|
3,181 |
2,740 |
$40K |
| 82746 |
|
4,952 |
4,426 |
$39K |
| 76882 |
|
985 |
820 |
$39K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
90 |
58 |
$39K |
| 77386 |
|
135 |
12 |
$38K |
| 84146 |
|
3,144 |
2,779 |
$36K |
| 90837 |
Psychotherapy, 53 minutes with patient |
1,085 |
518 |
$36K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
944 |
860 |
$36K |
| 82465 |
|
39,854 |
36,707 |
$36K |
| 83001 |
|
3,016 |
2,678 |
$36K |
| 86592 |
|
10,624 |
9,019 |
$34K |
| 82040 |
|
91,473 |
72,911 |
$34K |
| 87653 |
|
1,311 |
1,175 |
$34K |
| 88307 |
|
1,737 |
1,261 |
$34K |
| 86787 |
|
3,934 |
3,072 |
$33K |
| 87522 |
Neg quan hep c or qual rna |
1,198 |
1,072 |
$33K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
2,861 |
2,557 |
$32K |
| 88304 |
|
4,034 |
3,277 |
$32K |
| 86704 |
|
5,577 |
4,888 |
$31K |
| 81001 |
|
17,587 |
14,850 |
$30K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
163 |
106 |
$30K |
| 86225 |
|
4,194 |
3,498 |
$30K |
| 83735 |
|
42,257 |
25,184 |
$30K |
| 87077 |
|
11,636 |
9,056 |
$30K |
| 95912 |
|
84 |
68 |
$30K |
| 51729 |
|
91 |
78 |
$30K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,198 |
1,071 |
$29K |
| 84402 |
|
1,932 |
1,669 |
$29K |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
26 |
12 |
$29K |
| 73630 |
|
5,268 |
3,619 |
$29K |
| 95800 |
|
239 |
229 |
$29K |
| 83020 |
|
6,247 |
4,640 |
$28K |
| 76801 |
|
317 |
276 |
$28K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
537 |
273 |
$28K |
| 93976 |
|
334 |
293 |
$26K |
| 73502 |
|
2,399 |
1,974 |
$26K |
| 82533 |
|
4,979 |
3,562 |
$25K |
| 78306 |
|
137 |
103 |
$25K |
| 84165 |
|
6,561 |
5,210 |
$25K |
| 85652 |
|
20,914 |
17,041 |
$25K |
| 83002 |
|
2,161 |
1,880 |
$25K |
| 86618 |
|
3,387 |
2,571 |
$25K |
| 82274 |
|
2,066 |
1,963 |
$25K |
| 87186 |
|
9,403 |
7,288 |
$24K |
| 93225 |
|
485 |
406 |
$24K |
| J2357 |
Injection, omalizumab, 5 mg |
26 |
12 |
$24K |
| 82565 |
|
165,196 |
123,970 |
$23K |
| 43235 |
|
49 |
40 |
$23K |
| 86146 |
|
883 |
756 |
$23K |
| 90686 |
|
1,954 |
1,711 |
$23K |
| 95819 |
|
165 |
129 |
$23K |
| 86800 |
|
3,474 |
2,875 |
$22K |
| 72146 |
|
163 |
155 |
$22K |
| 97016 |
|
557 |
169 |
$22K |
| 74220 |
|
219 |
191 |
$22K |
| 86141 |
|
4,252 |
3,529 |
$22K |
| 82747 |
|
2,379 |
1,995 |
$21K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,617 |
1,815 |
$21K |
| 86376 |
|
2,963 |
2,508 |
$20K |
| 86334 |
|
3,369 |
2,645 |
$20K |
| 99215 |
Prolong outpt/office vis |
241 |
171 |
$20K |
| 85610 |
|
22,656 |
13,796 |
$20K |
| 86039 |
|
3,500 |
2,838 |
$20K |
| 84481 |
|
1,997 |
1,716 |
$19K |
| 80061 |
Lipid panel |
8,034 |
5,929 |
$19K |
| 20680 |
|
28 |
24 |
$19K |
| 83655 |
|
1,819 |
1,713 |
$19K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
942 |
444 |
$18K |
| 82247 |
|
77,425 |
61,956 |
$18K |
| 82088 |
|
1,454 |
1,167 |
$17K |
| 82024 |
|
1,907 |
1,630 |
$17K |
| 83880 |
|
7,260 |
5,575 |
$17K |
| 73110 |
|
1,789 |
1,451 |
$17K |
| 86850 |
|
19,839 |
14,850 |
$17K |
| 87338 |
|
1,481 |
1,385 |
$17K |
| 77334 |
|
75 |
41 |
$16K |
| 82627 |
|
1,246 |
1,119 |
$16K |
| 93296 |
|
1,131 |
921 |
$16K |
| 94726 |
|
393 |
353 |
$15K |
| 86200 |
|
2,631 |
2,185 |
$15K |
| 84480 |
|
2,500 |
2,160 |
$15K |
| 76857 |
|
277 |
234 |
$15K |
| 88112 |
|
1,145 |
904 |
$15K |
| 86705 |
|
3,100 |
2,614 |
$15K |
| 73610 |
|
3,095 |
2,481 |
$15K |
| 81003 |
|
48,541 |
39,205 |
$15K |
| 80053 |
Comprehensive metabolic panel |
20,942 |
13,284 |
$14K |
| 86359 |
|
2,388 |
2,014 |
$14K |
| 82652 |
|
644 |
543 |
$14K |
| 76000 |
|
99 |
83 |
$14K |
| 84154 |
|
1,167 |
1,023 |
$14K |
| 84425 |
|
1,129 |
1,001 |
$14K |
| 86430 |
|
4,823 |
3,980 |
$14K |
| 74178 |
|
67 |
61 |
$13K |
| 82785 |
|
1,628 |
1,302 |
$13K |
| 87070 |
|
7,707 |
6,169 |
$12K |
| 76981 |
|
1,340 |
1,192 |
$12K |
| 90677 |
|
108 |
97 |
$12K |
| 70546 |
|
27 |
24 |
$12K |
| 83520 |
|
2,206 |
1,783 |
$12K |
| 83690 |
|
19,281 |
15,382 |
$12K |
| 82523 |
|
1,843 |
1,499 |
$12K |
| 82950 |
|
2,957 |
2,696 |
$12K |
| 84156 |
|
8,812 |
6,713 |
$11K |
| 73562 |
|
683 |
455 |
$11K |
| 86708 |
|
1,423 |
1,296 |
$11K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
2,085 |
937 |
$11K |
| 74019 |
|
477 |
404 |
$11K |
| 86765 |
|
1,151 |
963 |
$11K |
| 72170 |
|
1,273 |
1,089 |
$11K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
45 |
28 |
$10K |
| 82550 |
|
10,057 |
8,115 |
$10K |
| 70498 |
|
1,509 |
1,196 |
$10K |
| 84080 |
|
2,034 |
1,666 |
$10K |
| 86162 |
|
1,008 |
829 |
$10K |
| 73200 |
|
151 |
123 |
$10K |
| 84244 |
|
1,373 |
1,171 |
$10K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
23,323 |
14,368 |
$10K |
| J0185 |
Injection, aprepitant, 1 mg |
64 |
38 |
$10K |
| 85730 |
|
5,213 |
4,050 |
$9K |
| 96401 |
|
495 |
225 |
$9K |
| 92611 |
|
83 |
77 |
$9K |
| 86617 |
|
1,100 |
482 |
$9K |
| 86735 |
|
955 |
806 |
$9K |
| 86256 |
|
1,336 |
1,119 |
$9K |
| 81420 |
Fetal chromosomal aneuploidy genomic sequence analysis panel |
25 |
19 |
$9K |
| 96910 |
|
330 |
87 |
$9K |
| 84295 |
|
134,804 |
102,279 |
$9K |
| 77062 |
|
749 |
669 |
$9K |
| 64415 |
|
79 |
69 |
$9K |
| 83883 |
|
952 |
697 |
$8K |
| 86304 |
|
1,985 |
1,445 |
$8K |
| 87529 |
|
245 |
227 |
$8K |
| 72157 |
|
52 |
43 |
$8K |
| 84166 |
|
1,258 |
945 |
$8K |
| 77061 |
|
713 |
610 |
$8K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
797 |
679 |
$8K |
| 86902 |
|
5,677 |
1,976 |
$8K |
| 13132 |
|
115 |
79 |
$8K |
| 83525 |
|
914 |
797 |
$8K |
| 51702 |
|
1,165 |
866 |
$7K |
| 87081 |
|
2,828 |
2,530 |
$7K |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
4,485 |
3,793 |
$7K |
| 97535 |
Self-care/home management training, each 15 minutes |
243 |
191 |
$7K |
| 70544 |
|
14 |
13 |
$7K |
| 51798 |
|
2,051 |
1,250 |
$7K |
| 85018 |
|
8,050 |
6,099 |
$7K |
| 85014 |
|
8,822 |
6,373 |
$7K |
| 84450 |
|
96,113 |
77,916 |
$7K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
668 |
530 |
$7K |
| 51784 |
|
101 |
88 |
$7K |
| 74230 |
|
83 |
77 |
$7K |
| 12032 |
|
102 |
74 |
$7K |
| 96133 |
|
111 |
69 |
$7K |
| 87625 |
|
289 |
261 |
$7K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
23 |
12 |
$6K |
| 98968 |
|
122 |
96 |
$6K |
| 86255 |
|
1,003 |
772 |
$6K |
| 10022 |
|
18 |
12 |
$6K |
| 85613 |
|
1,265 |
1,053 |
$6K |
| 29823 |
|
16 |
13 |
$6K |
| 94660 |
|
151 |
94 |
$6K |
| 99443 |
|
579 |
275 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
4,979 |
3,339 |
$6K |
| 83921 |
|
669 |
573 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
78 |
69 |
$6K |
| 62328 |
|
14 |
12 |
$6K |
| 84478 |
|
39,936 |
36,762 |
$6K |
| 36591 |
|
1,663 |
711 |
$5K |
| 84207 |
|
368 |
312 |
$5K |
| 89230 |
|
116 |
107 |
$5K |
| 83835 |
|
868 |
727 |
$5K |
| 93308 |
|
49 |
37 |
$5K |
| 82340 |
|
2,193 |
1,794 |
$5K |
| 86694 |
|
446 |
409 |
$5K |
| 87205 |
|
5,966 |
4,477 |
$5K |
| 84432 |
|
1,051 |
885 |
$5K |
| 86335 |
|
456 |
364 |
$5K |
| 73560 |
|
3,855 |
3,058 |
$5K |
| 73080 |
|
833 |
687 |
$5K |
| 84445 |
|
200 |
182 |
$4K |
| 78264 |
|
18 |
15 |
$4K |
| 87631 |
|
1,035 |
840 |
$4K |
| 86364 |
|
503 |
374 |
$4K |
| 93270 |
|
486 |
384 |
$4K |
| 81025 |
|
22,640 |
19,103 |
$4K |
| 96411 |
|
107 |
43 |
$4K |
| 80164 |
|
696 |
558 |
$4K |
| 87147 |
|
1,943 |
1,718 |
$4K |
| 84144 |
|
221 |
157 |
$4K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
18 |
12 |
$4K |
| 82150 |
|
977 |
829 |
$4K |
| 82248 |
|
42,031 |
31,452 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,222 |
4,271 |
$3K |
| 85007 |
|
8,841 |
5,551 |
$3K |
| 99442 |
|
278 |
136 |
$3K |
| 86880 |
|
131 |
114 |
$3K |
| 93786 |
|
55 |
42 |
$3K |
| 73590 |
|
798 |
623 |
$3K |
| 84300 |
|
1,706 |
1,326 |
$3K |
| 83721 |
|
2,219 |
1,966 |
$3K |
| 95924 |
|
17 |
12 |
$3K |
| 95816 |
|
16 |
14 |
$3K |
| 86757 |
|
238 |
206 |
$3K |
| 81015 |
|
26,396 |
21,550 |
$3K |
| 93297 |
|
267 |
236 |
$3K |
| 82103 |
|
399 |
345 |
$3K |
| 82378 |
|
1,627 |
1,187 |
$3K |
| 81050 |
|
1,698 |
1,475 |
$3K |
| 98967 |
|
57 |
46 |
$3K |
| 11721 |
|
180 |
127 |
$3K |
| 95249 |
|
90 |
63 |
$3K |
| 82390 |
|
371 |
331 |
$2K |
| 85045 |
|
9,098 |
4,778 |
$2K |
| 88173 |
|
1,003 |
800 |
$2K |
| 90694 |
|
478 |
382 |
$2K |
| 87641 |
|
109 |
97 |
$2K |
| 64642 |
|
18 |
13 |
$2K |
| 87640 |
|
122 |
112 |
$2K |
| 97163 |
|
40 |
40 |
$2K |
| 96116 |
|
50 |
40 |
$2K |
| 80051 |
|
4,270 |
2,505 |
$2K |
| 82164 |
|
323 |
261 |
$2K |
| 76604 |
|
550 |
438 |
$2K |
| 82330 |
|
5,991 |
3,773 |
$2K |
| 93280 |
|
262 |
227 |
$2K |
| 85379 |
|
3,897 |
3,179 |
$2K |
| 84155 |
|
76,857 |
60,856 |
$2K |
| 87075 |
|
2,158 |
1,520 |
$2K |
| 87469 |
|
175 |
169 |
$2K |
| 87015 |
|
1,381 |
1,124 |
$2K |
| 96132 |
|
52 |
41 |
$2K |
| 80177 |
|
262 |
240 |
$2K |
| 87468 |
|
171 |
166 |
$2K |
| 84460 |
|
98,187 |
79,384 |
$2K |
| 87484 |
|
171 |
166 |
$2K |
| 93298 |
|
191 |
169 |
$2K |
| 73521 |
|
53 |
48 |
$2K |
| 86696 |
|
114 |
107 |
$2K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
27 |
27 |
$2K |
| 80076 |
|
2,538 |
1,653 |
$2K |
| 74181 |
|
15 |
13 |
$2K |
| 83615 |
|
16,714 |
9,434 |
$2K |
| 87046 |
|
365 |
315 |
$2K |
| 11301 |
|
55 |
43 |
$2K |
| 82977 |
|
3,067 |
2,712 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
29 |
26 |
$2K |
| 84550 |
|
6,037 |
4,745 |
$2K |
| 97166 |
|
45 |
38 |
$2K |
| 84540 |
|
840 |
632 |
$2K |
| 87045 |
|
365 |
315 |
$2K |
| 86258 |
|
171 |
87 |
$1K |
| 82525 |
|
293 |
254 |
$1K |
| 87517 |
|
66 |
64 |
$1K |
| 87449 |
|
367 |
307 |
$1K |
| 93285 |
|
54 |
52 |
$1K |
| 86769 |
|
41 |
35 |
$1K |
| 70480 |
|
13 |
12 |
$1K |
| 84520 |
|
151,581 |
114,756 |
$1K |
| 83498 |
|
76 |
66 |
$1K |
| 93923 |
|
16 |
13 |
$1K |
| 88312 |
|
2,344 |
1,704 |
$1K |
| 83993 |
|
103 |
91 |
$1K |
| 90662 |
|
178 |
131 |
$1K |
| 84484 |
|
20,812 |
14,979 |
$1K |
| 77073 |
|
16 |
16 |
$1K |
| 87324 |
|
296 |
247 |
$1K |
| 93880 |
|
19 |
12 |
$1K |
| 73140 |
|
354 |
320 |
$1K |
| 86695 |
|
114 |
107 |
$1K |
| 86666 |
|
121 |
100 |
$1K |
| 84075 |
|
79,478 |
63,863 |
$1K |
| 76775 |
|
387 |
289 |
$1K |
| 90732 |
|
29 |
28 |
$1K |
| 96137 |
|
19 |
13 |
$1K |
| 72202 |
|
27 |
26 |
$1K |
| 87209 |
|
149 |
125 |
$1K |
| 84305 |
|
175 |
145 |
$992.67 |
| 99441 |
|
185 |
87 |
$971.36 |
| 82085 |
|
250 |
209 |
$937.62 |
| 93299 |
|
44 |
38 |
$877.52 |
| 92610 |
|
14 |
12 |
$843.60 |
| 87040 |
|
3,452 |
1,744 |
$835.98 |
| 85660 |
|
5,362 |
2,067 |
$792.13 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
146 |
114 |
$791.36 |
| 82962 |
|
23,528 |
8,631 |
$763.88 |
| 96136 |
|
49 |
39 |
$761.07 |
| 87177 |
|
149 |
125 |
$723.17 |
| G0378 |
Hospital observation service, per hour |
12,249 |
5,724 |
$711.36 |
| 87116 |
|
583 |
438 |
$702.68 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,358 |
6,363 |
$701.86 |
| 84436 |
|
238 |
204 |
$695.36 |
| 64447 |
|
78 |
70 |
$665.29 |
| 83519 |
|
47 |
42 |
$641.25 |
| 80069 |
|
1,001 |
753 |
$632.67 |
| 83605 |
|
8,013 |
5,742 |
$591.12 |
| 76870 |
|
140 |
131 |
$574.04 |
| 87807 |
|
324 |
289 |
$571.01 |
| 87207 |
|
431 |
375 |
$554.98 |
| 84100 |
|
25,361 |
14,986 |
$554.03 |
| 86709 |
|
111 |
103 |
$546.29 |
| 96523 |
|
37 |
25 |
$535.91 |
| 96402 |
|
52 |
38 |
$534.26 |
| 87252 |
|
36 |
26 |
$527.66 |
| 82232 |
|
258 |
195 |
$523.62 |
| 82374 |
|
132,241 |
100,487 |
$510.91 |
| 87102 |
|
600 |
435 |
$499.95 |
| 86753 |
|
39 |
26 |
$489.75 |
| 84630 |
|
118 |
107 |
$489.15 |
| 86923 |
|
4,318 |
1,648 |
$488.29 |
| 82951 |
|
51 |
44 |
$479.31 |
| 94727 |
|
4,581 |
3,865 |
$431.64 |
| G0008 |
Administration of influenza virus vaccine |
980 |
729 |
$424.20 |
| 82438 |
|
128 |
119 |
$412.23 |
| 82010 |
|
1,244 |
945 |
$408.38 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
4,385 |
3,739 |
$406.44 |
| 86308 |
|
521 |
458 |
$397.06 |
| 84446 |
|
49 |
39 |
$395.09 |
| 84133 |
|
266 |
196 |
$388.83 |
| 82435 |
|
132,555 |
100,659 |
$382.62 |
| 88302 |
|
43 |
39 |
$368.64 |
| 86036 |
|
72 |
56 |
$358.87 |
| 73060 |
|
19 |
14 |
$358.24 |
| S0028 |
Injection, famotidine, 20 mg |
858 |
427 |
$352.00 |
| J1097 |
Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml |
74 |
52 |
$337.05 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
64 |
56 |
$325.04 |
| 74455 |
|
47 |
37 |
$301.73 |
| 86901 |
|
21,499 |
15,284 |
$287.29 |
| 84681 |
|
26 |
25 |
$281.53 |
| 97164 |
|
40 |
36 |
$277.86 |
| 94618 |
|
13 |
12 |
$257.29 |
| 76377 |
|
791 |
590 |
$239.02 |
| 71101 |
|
34 |
28 |
$233.08 |
| 83010 |
|
124 |
101 |
$214.92 |
| 82140 |
|
95 |
63 |
$209.90 |
| 11901 |
|
12 |
12 |
$186.17 |
| 82239 |
|
13 |
12 |
$179.96 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
13,727 |
10,769 |
$179.61 |
| 82803 |
|
1,485 |
1,089 |
$171.59 |
| 86677 |
|
17 |
14 |
$170.45 |
| 87206 |
|
594 |
432 |
$167.56 |
| 86645 |
|
18 |
14 |
$160.90 |
| 85049 |
|
106 |
71 |
$160.82 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
5,049 |
4,336 |
$160.73 |
| 82530 |
|
13 |
12 |
$159.60 |
| 95012 |
|
178 |
172 |
$159.42 |
| 82575 |
|
30 |
24 |
$153.34 |
| 86644 |
|
19 |
14 |
$151.25 |
| 87107 |
|
20 |
12 |
$147.90 |
| 82952 |
|
45 |
39 |
$130.90 |
| 86431 |
|
57 |
54 |
$126.60 |
| 89051 |
|
124 |
104 |
$124.32 |
| 51701 |
|
187 |
139 |
$122.89 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
27,349 |
19,718 |
$122.69 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
131 |
104 |
$105.77 |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
592 |
471 |
$102.00 |
| 90715 |
|
1,020 |
877 |
$101.37 |
| 82787 |
|
12 |
12 |
$93.29 |
| 73090 |
|
45 |
38 |
$89.56 |
| 85240 |
|
18 |
12 |
$85.50 |
| 85705 |
|
14 |
13 |
$84.35 |
| 84560 |
|
37 |
30 |
$80.37 |
| 96376 |
|
13,988 |
5,791 |
$77.16 |
| 80178 |
|
51 |
36 |
$74.93 |
| 85008 |
|
2,968 |
2,287 |
$72.84 |
| G0001 |
|
477 |
335 |
$69.81 |
| 82553 |
|
44 |
26 |
$66.12 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
585 |
382 |
$65.62 |
| J1836 |
Injection, metronidazole, 10 mg |
705 |
338 |
$64.01 |
| 82985 |
|
12 |
12 |
$58.81 |
| 82308 |
|
15 |
13 |
$51.16 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
31,387 |
23,512 |
$47.72 |
| 86593 |
|
13 |
12 |
$46.20 |
| 82610 |
|
14 |
12 |
$38.94 |
| 94729 |
|
5,384 |
4,563 |
$38.72 |
| 73501 |
|
14 |
12 |
$36.70 |
| 84105 |
|
17 |
12 |
$34.58 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
209 |
154 |
$25.30 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
4,925 |
1,820 |
$24.10 |
| 87181 |
|
71 |
55 |
$23.49 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
26,701 |
16,888 |
$22.89 |
| 85048 |
|
14 |
13 |
$21.78 |
| 84145 |
|
2,521 |
1,916 |
$21.77 |
| 86300 |
|
38 |
25 |
$19.87 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
28,997 |
17,895 |
$19.69 |
| 83935 |
|
18 |
12 |
$19.53 |
| 83930 |
|
30 |
26 |
$18.93 |
| J2704 |
Injection, propofol, 10 mg |
33,816 |
25,690 |
$18.85 |
| J3490 |
Unclassified drugs |
390,026 |
91,775 |
$15.52 |
| J2598 |
Injection, vasopressin, 1 unit |
23 |
12 |
$15.44 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
2,360 |
2,048 |
$15.41 |
| 88313 |
|
239 |
154 |
$13.44 |
| J0687 |
Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg |
227 |
138 |
$11.72 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
38,318 |
27,043 |
$9.93 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
6,605 |
4,325 |
$7.05 |
| A9270 |
Non-covered item or service |
10,605 |
4,475 |
$7.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
19,312 |
15,515 |
$6.65 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
4,789 |
3,592 |
$6.63 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
419 |
350 |
$6.28 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
28,327 |
20,685 |
$5.58 |
| J7050 |
Infusion, normal saline solution, 250 cc |
9,216 |
4,733 |
$5.10 |
| 90656 |
|
45 |
43 |
$4.45 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
6,114 |
4,214 |
$3.18 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,159 |
2,375 |
$2.94 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
987 |
683 |
$2.86 |
| J2060 |
Injection, lorazepam, 2 mg |
1,916 |
1,314 |
$2.83 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
20,185 |
8,886 |
$2.76 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
3,104 |
1,961 |
$2.75 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
972 |
674 |
$2.62 |
| J1630 |
Injection, haloperidol, up to 5 mg |
3,365 |
2,670 |
$2.01 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
1,485 |
950 |
$1.98 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
7,480 |
4,410 |
$1.98 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
4,968 |
3,467 |
$1.94 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
12,448 |
10,078 |
$1.87 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
25,106 |
14,918 |
$1.63 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
460 |
315 |
$1.60 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
1,715 |
1,188 |
$1.05 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
409 |
287 |
$0.96 |
| J1644 |
Injection, heparin sodium, per 1000 units |
13,014 |
4,505 |
$0.95 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
420 |
272 |
$0.82 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
21,619 |
15,506 |
$0.71 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
16,070 |
7,527 |
$0.50 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
5,212 |
2,675 |
$0.24 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
23 |
13 |
$0.07 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
20 |
13 |
$0.06 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
22 |
12 |
$0.06 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
19 |
13 |
$0.05 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
17 |
12 |
$0.05 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
19 |
13 |
$0.05 |
| J3590 |
Unclassified biologics |
814 |
645 |
$0.00 |
| C1769 |
Guide wire |
3,941 |
2,903 |
$0.00 |
| J1815 |
Injection, insulin, per 5 units |
5,767 |
1,804 |
$0.00 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
8,025 |
4,706 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
18,278 |
12,134 |
$0.00 |
| 94760 |
|
6,820 |
5,571 |
$0.00 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
6,613 |
2,149 |
$0.00 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
272 |
210 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
1,022 |
726 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
503 |
353 |
$0.00 |
| J1790 |
Injection, droperidol, up to 5 mg |
501 |
365 |
$0.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
602 |
350 |
$0.00 |
| J2785 |
Injection, regadenoson, 0.1 mg |
869 |
658 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
1,161 |
577 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
1,924 |
767 |
$0.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
354 |
217 |
$0.00 |
| 82945 |
|
177 |
143 |
$0.00 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
1,836 |
1,438 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
11,764 |
3,872 |
$0.00 |
| 88185 |
|
685 |
569 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
1,396 |
1,226 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
732 |
307 |
$0.00 |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
311 |
293 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
454 |
288 |
$0.00 |
| 88341 |
|
2,161 |
1,581 |
$0.00 |
| 95886 |
|
2,889 |
2,542 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
1,293 |
643 |
$0.00 |
| 84157 |
|
200 |
160 |
$0.00 |
| 96368 |
|
648 |
388 |
$0.00 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
215 |
203 |
$0.00 |
| 95885 |
|
563 |
483 |
$0.00 |
| A9698 |
Non-radioactive contrast imaging material, not otherwise classified, per study |
491 |
452 |
$0.00 |
| J1094 |
Injection, dexamethasone acetate, 1 mg |
2,341 |
1,622 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
2,106 |
1,461 |
$0.00 |
| C9359 |
Porous purified collagen matrix bone void filler (integra mozaik osteoconductive scaffold putty, integra os osteoconductive scaffold putty), per 0.5 cc |
1,243 |
1,047 |
$0.00 |
| 99402 |
|
734 |
588 |
$0.00 |
| 51600 |
|
77 |
62 |
$0.00 |
| 94761 |
|
821 |
693 |
$0.00 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
113 |
76 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
2,997 |
1,134 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
154 |
80 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
201 |
177 |
$0.00 |
| V2632 |
Posterior chamber intraocular lens |
103 |
67 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
704 |
569 |
$0.00 |
| 51797 |
|
69 |
62 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
230 |
183 |
$0.00 |
| J9045 |
Injection, carboplatin, 50 mg |
70 |
38 |
$0.00 |
| Q3014 |
Telehealth originating site facility fee |
769 |
619 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
1,104 |
980 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
1,635 |
1,205 |
$0.00 |
| 17312 |
|
108 |
71 |
$0.00 |
| 29826 |
|
25 |
25 |
$0.00 |
| 88311 |
|
90 |
66 |
$0.00 |
| 22614 |
|
66 |
51 |
$0.00 |
| 82810 |
|
26 |
13 |
$0.00 |
| 22842 |
|
48 |
38 |
$0.00 |
| 64450 |
|
16 |
15 |
$0.00 |
| J9267 |
Injection, paclitaxel, 1 mg |
87 |
38 |
$0.00 |
| 11302 |
|
22 |
13 |
$0.00 |
| 73552 |
|
16 |
12 |
$0.00 |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
15 |
12 |
$0.00 |
| Q4114 |
Integra flowable wound matrix, injectable, 1 cc |
13 |
12 |
$0.00 |
| 12001 |
|
12 |
12 |
$0.00 |
| A4648 |
Tissue marker, implantable, any type, each |
14 |
13 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
46 |
12 |
$0.00 |
| C1776 |
Joint device (implantable) |
1,794 |
1,580 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,760 |
2,216 |
$0.00 |
| J1756 |
Injection, iron sucrose, 1 mg |
2,913 |
1,347 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
11,922 |
8,451 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
1,556 |
1,205 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
2,152 |
1,595 |
$0.00 |
| A4649 |
Surgical supply; miscellaneous |
237 |
201 |
$0.00 |
| 17003 |
|
3,495 |
2,597 |
$0.00 |
| 86922 |
|
2,320 |
782 |
$0.00 |
| 76942 |
|
204 |
161 |
$0.00 |
| 77002 |
|
1,861 |
1,595 |
$0.00 |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
882 |
741 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
3,199 |
1,991 |
$0.00 |
| 11101 |
|
286 |
215 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
1,334 |
939 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
7,804 |
4,413 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
14,203 |
12,136 |
$0.00 |
| 93226 |
|
485 |
406 |
$0.00 |
| J1956 |
Injection, levofloxacin, 250 mg |
19 |
12 |
$0.00 |
| 11103 |
|
929 |
707 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
96 |
85 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
4,543 |
2,867 |
$0.00 |
| 99152 |
|
1,481 |
1,076 |
$0.00 |
| J3489 |
Injection, zoledronic acid, 1 mg |
499 |
405 |
$0.00 |
| 99401 |
|
108 |
96 |
$0.00 |
| 85347 |
|
129 |
63 |
$0.00 |
| 88360 |
|
98 |
78 |
$0.00 |
| 95874 |
|
36 |
26 |
$0.00 |
| S0077 |
Injection, clindamycin phosphate, 300 mg |
513 |
329 |
$0.00 |
| 20936 |
|
124 |
100 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
174 |
121 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
2,801 |
2,060 |
$0.00 |
| 99001 |
|
1,210 |
1,006 |
$0.00 |
| 77003 |
|
431 |
322 |
$0.00 |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
292 |
144 |
$0.00 |
| C1758 |
Catheter, ureteral |
49 |
40 |
$0.00 |
| C1729 |
Catheter, drainage |
59 |
40 |
$0.00 |
| 51741 |
|
73 |
64 |
$0.00 |
| 90653 |
|
133 |
127 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
27 |
24 |
$0.00 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
238 |
100 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
212 |
180 |
$0.00 |
| 93356 |
|
58 |
49 |
$0.00 |
| Q9958 |
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml |
61 |
52 |
$0.00 |
| 20930 |
|
140 |
119 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
233 |
119 |
$0.00 |
| Q0177 |
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
345 |
218 |
$0.00 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
20 |
13 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
488 |
396 |
$0.00 |
| 22853 |
|
16 |
16 |
$0.00 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
20 |
17 |
$0.00 |
| 82042 |
|
13 |
12 |
$0.00 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
268 |
184 |
$0.00 |
| 98960 |
|
22 |
22 |
$0.00 |
| 95923 |
|
17 |
12 |
$0.00 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
129 |
123 |
$0.00 |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
15 |
12 |
$0.00 |
| C1762 |
Connective tissue, human (includes fascia lata) |
13 |
12 |
$0.00 |
| 36600 |
|
15 |
12 |
$0.00 |
| 11105 |
|
44 |
25 |
$0.00 |